Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections

被引:29
|
作者
Patel, Ursula C. [1 ]
McKissic, Erin L. [2 ]
Kasper, Douglas [3 ]
Lentino, Joseph R. [3 ]
Pachucki, Constance T. [3 ]
Lee, Todd [4 ]
Lopansri, Bert K. [3 ]
机构
[1] Edward Hines Jr VA Hosp, Dept Pharm 119, Hines, IL 60141 USA
[2] Edward Hines Jr VA Med Ctr, Dept Pharm, Hines, IL USA
[3] Edward Hines Jr VA Med Ctr, Med Serv, Sect Infect Dis, Hines, IL USA
[4] Edward Hines Jr VA Med Ctr, Dept Res, Hines, IL USA
关键词
Bacteremia; Ceftriaxone; MSSA; S; aureus; United States; Veterans; PARENTERAL ANTIMICROBIAL THERAPY; PROTEIN-BINDING; BACTEREMIA; IMPACT;
D O I
10.1007/s11096-014-9999-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Standard of care therapy (SOCT) for the treatment of methicillin susceptible staphylococcal aureus (MSSA) infections requires multiple daily infusions. Despite questionable efficacy due to high protein binding, ceftriaxone (CTX) is frequently used for treatment of MSSA at Hines VA Hospital. Objective The objective of this study was to determine clinical and microbiological outcomes in patients with MSSA bacteremia treated with CTX compared to SOCT. Setting This retrospective study was conducted at the Edward Hines, Jr. VA Hospital which is a comprehensive health care center serving the veteran population of the greater metropolitan Chicago and northwest Indiana regions and is institutionally affiliated with the Loyola University Medical Center. The Hines VA provides medical care to over 56,000 veterans and operates approximately 500 hospital beds, including acute care and nursing home beds. Method We conducted a retrospective cohort study of patients with MSSA bacteremia treated at Hines VA Hospital between January 2000 and September 2009. Patients who received either SOCT or CTX for > 50 % of the treatment course and for the appropriate duration were included. Patients who were on multiple antibiotics concurrently or who received < 14 days of therapy were excluded. Main outcome measure The primary outcome of this study is to compare clinical outcomes of patients with MSSA bacteremia who were treated with CTX compared to those who received standard of care agents. Results Ninety-three patients with MSSA bacteremia were included in the analysis. Fifty-one were treated with SOCT and 42 with CTX. There were no differences in microbiological cure between SOCT (94.1 %) and CTX (95.2 %) (p = 0.812). Clinical cure was similar between groups (74.5 % for SOCT, 83.3 % for CTX) (p = 0.303). CTX was used more often to treat Staphylococcus aureus bacteremia associated with osteomyelitis whereas endocarditis and central line associated infections were treated more frequently with SOCT (p = 0.01). More patients treated with CTX were managed in the ambulatory setting (64 vs. 24 %; p = < 0.001). There was a trend toward a longer hospital stay with SOCT. Conclusion Clinical outcomes for MSSA bacteremia did not differ significantly between patients treated with CTX and SOCT. Findings suggest that CTX may be an alternative for outpatient management of MSSA bacteremia.
引用
收藏
页码:1282 / 1289
页数:8
相关论文
共 50 条
  • [21] Clonal complex 398 methicillin-susceptible Staphylococcus aureus bloodstream infections are associated with high mortality
    Bouiller, K.
    Gbaguidi-Haore, H.
    Hocquet, D.
    Cholley, P.
    Bertrand, X.
    Chirouze, C.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (05) : 451 - 455
  • [22] The Role of Combination Therapy in Critically Ill Patients With Methicillin-susceptible Staphylococcus aureus Bloodstream Infections: Does The Question Remain? Reply
    Cheng, Matthew P.
    Lawandi, Alexander
    Butler-Laporte, Guillaume
    De l'Etoile-Morel, Samuel
    Paquette, Katryn
    Lee, Todd C.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : 168 - 169
  • [23] Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone
    S. A. Winans
    A. M. Luce
    R. Hasbun
    Infection, 2013, 41 : 769 - 774
  • [24] Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia
    Yetmar, Zachary A.
    Khodadadi, Ryan B.
    Go, John Raymond
    Chesdachai, Supavit
    Abu Saleh, Omar M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (04) : 423 - 430
  • [25] Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone
    Winans, S. A.
    Luce, A. M.
    Hasbun, R.
    INFECTION, 2013, 41 (04) : 769 - 774
  • [26] Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia
    Zachary A. Yetmar
    Ryan B. Khodadadi
    John Raymond Go
    Supavit Chesdachai
    Omar M. Abu Saleh
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 423 - 430
  • [27] Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections
    Kener, Daisy
    Childress, Darrell
    Andrus, Ian
    Olson, Jared
    Webb, Brandon
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):
  • [28] Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia
    Davie Wong
    Titus Wong
    Marc Romney
    Victor Leung
    Annals of Clinical Microbiology and Antimicrobials, 15
  • [29] A molecular epidemiological investigation of methicillin-susceptible Staphylococcus aureus causing bloodstream infections in Ireland, 2006–2017
    Emily C. Deasy
    Gráinne I. Brennan
    Sarah C. Tecklenborg
    Chioma Umeh
    David C. Coleman
    Anna C. Shore
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 927 - 936
  • [30] The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections
    Lauren K. Flynt
    Rachel M. Kenney
    Marcus J. Zervos
    Susan L. Davis
    Infectious Diseases and Therapy, 2017, 6 : 225 - 231